News
ARISTA Biotech Confirms the Sensitivity of Rapid Antigen Test against Emerging Omicron Sub-Lineages BA.4 and BA.5
Performance was found to be similar to the detection sensitivity against the original virus.
Read MorePerformance was found to be similar to the detection sensitivity against the original virus.
Read MoreWith regard to Covid-19 testing, there is a common misunderstanding between antigen rapid tests and antibody rapid tests – and their applied use. They are both Covid-19 tests, but they differ in their test target, sample methods, timing, and applications of use.
Read MoreAuthorization has been granted by the South African Health Products Regulatory Authority (SAHPRA), in terms of Section 21 of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) for the sale of the ARISTA COVID-19 Antigen Rapid Test for professional use.
The short answer is yes, and yes. According to the United States Centres for Disease Control and Prevention (CDC), those who do not get vaccinated after their recovery from Covid-19 are more likely to be infected again compared to those who get a jab after their recovery. It is for this reason that many health authorities advise a booster after infection. The guidelines vary from country to country with most recommending at least a 4-week wait after infection before getting a booster.
In one of the BIGGEST industry announcements to date – Rapid Antigen Tests (RATs) will now be available for use by ordinary citizens and clinics in China. Despite being the world’s major supplier RATs, China had previously prohibited their domestic use. Given the latest move, we would expect to see a squeeze on the global supply chain and pricing.
ARISTA Biotech commenced the new year with regulatory approval to market their ARISTA™ COVID-19 Antigen Rapid Test in Indonesia and Thailand – adding to an already well-established network in South East Asia that now includes: Brunei Darussalam, Indonesia, Malaysia, Singapore, Thailand, and Vietnam.
Contact us at info@aristabio.com if you would like to partner with us in Cambodia, Laos, Myanmar, or Philippines.